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SUMMARY
Hepatocellular carcinoma (HCC) is an important type of cancer etiologically related to some viruses, chemical carcinogens and
other host or environmental factors associated to chronic liver injury in humans. The tumor suppressor gene p53 is mutated in highly
variable levels (0-52%) of HCC in different countries. OBJECTIVE. The objective of the present study was to compare the frequency
of aberrant immunohistochemical expression of p53 in HCC occurring in cirrhotic or in non-cirrhotic patients as well as in liver cell
dysplasia and in adenomatous hyperplasia. We studied 84 patients with HCC or cirrhosis. RESULTS. We detected p53 altered
immuno-expression in 58.3% of patients in Grade III-IV contrasting to 22.2% of patients in Grade I-II (p = 0.02). Nontumorous areas
either in the vicinity of HCC or in the 30 purely cirrhotic cases showed no nuclear p53 altered expression, even in foci of dysplasia or
adenomatous hyperplasia. No significant difference was found among cases related to HBV, HCV or alcohol. CONCLUSION. The
high frequency of p53 immunoexpression in this population is closer to those reported in China and Africa, demanding further studies
to explain the differences with European and North American reports.
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INTRODUCTION
Hepatocellular Carcinoma (HCC) is the most frequent type of primary
liver cancer and one of the commonest cancers worldwide, and, in some
countries in Asia and Africa, a leading cause of deaths50. Due to its
heterogeneous geographical distribution, HCC has been instrumental in
the identification of major risk factors. HCC is etiologically linked to
viruses (Hepatitis B and Hepatitis C), chemical carcinogens (aflatoxins)
and other host or environmental factors that cause chronic liver injury8,9,45.
These factors trigger a sequence of events leading to malignant
transformation of liver parenchymal cells. Indeed, the previously normal
liver (quiescent cells) after chronic exposure to different risk factors, in
advanced stages of cirrhosis with repetitive bouts of cell death,
regeneration and proliferation acquire preneoplastic features. The
oxidative stress and the inflammatory cytokines liberation triggered by
this process may cause serious genetic lesions that govern cell
proliferation (clonal distribution) and the genesis of the tumour.
Since 1991, genetic studies have shown high prevalence of point
mutations in p53 in southern Africa and in the region of Qidong, China,
areas with high prevalence of viral infections as well as high concentration
of aflatoxins in dietary intake23,30. The prevalence is much lower in other
parts of the world.
Cancer cells are characterized by unrestrained growth which may be
due to an imbalance between cell proliferation and death. Recently,
several studies have shown that various types of alterations in cell cycle
regulators are found in many kinds of cancer. p21Waf1/Cip1 (p21) and p27Kip1
(p27) are part of this cell cycle regulators31. They belong to a family of
genes, which negatively regulate the cell cycle, therefore, inhibiting the
cell proliferation. The cell cycle is positively controlled by complex of
cyclins and cyclin-dependent kinases (CDK)11,50. The main substrate of
cyclin and CDK is the retinoblastoma gene product (Rb). Phosphorylation
of Rb by cyclin/CDK complex allows progression of the cell cycle. p21
and p27 by binding to cyclin/CDK abrogate their activity40,41,43.
Consequently, Rb is not phosphorylated and cell cycle progression is
arrested. Hence, p21 and p27 are small proteins that have the ability to
halt the cell cycle proliferation by inhibiting the cyclin/CDK complex,
acting as tumour growth suppressors. Loss or decreased expressions of
p21 and/or p27 may facilitate the proliferation of cancer cells.
It is accepted that cancer proceeds through the accumulation of
mutations in genes that govern cell proliferation and death. In recent
years, the most commonly observed genetic alterations in HCC, as well
as in many other tumours affecting humans, have been reported to be
the mutations of p53 gene50.
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The anti-oncogene p53 is located on chromosome 17p and contains
11 exon interrupted by 10 introns, down-regulates cell proliferation by
coding for a nuclear phosphoprotein which binds to specific DNA
sequencies, arresting cell growth at late G1 phase of the cell cycle. This
protein has a half-life of about 20 minutes and so is not regularly
detectable by immunohistochemistry (IHC).
Most p53 mutations are missense and produce a faulty protein called
mp53, functionally inactive but chemically stable. So, this gene has the
features of a tumour suppressor gene in its wild type form and can be a
dominant oncogene in its mutated form. Since its discovery two decades
ago, the diverse role of p53 provided an explanation why mutations in
this gene drive a normal cell towards cancer31.
The most common techniques used for p53 mutation detection
include PCR based assays like Single Strand Conformational
Polymorphism (SSCP), Denaturing Gradient Gel Electrophoresis
(DGGE)26 and DNA Sequencing. Recently, another method based on
yeast functional assay was developed to detect p53 mutations. However,
most genetic alterations are point mutations between codons 120 and
290 of the 393 amino-acid residues leading to mp53 and these can be
detectable in the liver cell nucleus by IHC.
The p53 gene is mutated in about 27% of HCCs worldwide11. All
reported p53 mutations in HCC are somatic; therefore, germ line
mutations of p53 appear not to predispose to HCC. Recently, the p53
overexpression was associated with poor prognosis in patients with
HCC28.
Both the frequency and the type of p53 mutations are different
depending on geographic location and suspected etiology of these tumors.
The frequency of all p53 mutations varies between 0 to 20% in North
America and Europe and 42 to 52% in China. Although these mutations
may be present independent of HBV or HCV infection, some studies
describes higher indexes with aflatoxin exposure, either alone or
associated to viral infections50 (Table 1).
The mutational spectrum of p53 gene associated to a given tumor is
important in the etiology of cancer and it can be exploited to therapeutic
and prognostic aims. Cancers presenting p53 mutations tend to be more
aggressive and chemotherapy resistant than cancer of similar tissues
expressing wild type p53.
Since most missense mutations of p53 produce stable protein, high
levels of agreement are shown between IHC and genetic studies. However,
a mutant case could result negative at IHC due to excessive fixation or
when the genetic alteration is a delection or a non-sense mutation, with
no production of any p53 protein.
On the opposite, IHC may result positive in the absence of mutation,
for instance when there is an abnormal accumulation of non-mutated
p53 protein, most probably related to post-transcriptional phenomena.
Table 1
Frequency and type of alteration and the methodology applied worldwide *
Geographical area Alteration rate Affected codon Method Correlations Ref.
United States 6/30 exons 4-8 IHC, SSCP HCV 28
(20%)
Alaska 0/13 —— PCR sequence —— 13
Japan 123/439 exons 5-8 SSCP, PCR 17p and 13q LOHs, viral hepatitis, 21
(28%) sequence late tumor stage, large tumor gradelarge
tumor size, poor differentiation
Thailand 2/15 249,254 PCR sequence —— 22
(13%)
China (Qidong/ Shanghai) 73/139 Mostly 249 PCR sequence HBV, AFB1, 17p LOH, 4q LOH 20, 47
(52%)
China (Hong Kong) 6/21 exons 5-9 PCR sequence Progression 37
(29%) (249:13%)
Taiwan 66/211 exons 5-8 PCR sequence, Late tumor stage, HBV/AFB1/249 15
(31%) (249:13%) SSCP, IHC
Germany 10/55 exons 5-8 SSCP, PCR, —— 31
(18%) cloning
Britain 59/231 exons 5-8 SSCP, DGGE Viral hepatitis, poor prognosis 10
(25%) haemochromatosis (220)
France 9/58 —— IHC Viral hepatitis, tumor size, invasion 32
(15%)
Spain 0/129 —— SSCP, IHC —— 5
Mozambique 5/10 249 PCR sequence 17P LOH, AFB1 6
(50%), 249
Senegal 10/15 249 PCR sequence AFB1 12
(67%), 249
Australia 0/15 —— PCR sequence —— 50
* Modified from BUENDIA, 20007.
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Since major functions of p53 in the cell cycle and cell transformation
are performed directly by its protein, IHC may serve as a very useful
tool for the study of p53 alterations in carcinogenesis57.
The development of HCC appears to be preceded by liver cell
dysplasia, a condition subject to controversy and confusion. First,
ANTHONY et al.3 suggested the preneoplastic capacity of liver cell
dysplasia and then several studies have stressed the relation with
carcinoma. Recently, LIBBRECHT et al.38 investigated the predictive
value of small and large cell dysplasia, revealing large cell dysplasia as
an identifier of patients at risk for developing HCC.
In Japan, the presence of a large regenerative nodule within a cirrhotic
liver, referred to as a macroregenerative nodule or adenomatous
hyperplasia is thought to play a role in the pathogenesis of hepatocellular
carcinoma4. In hepatocarcinogenesis of the cirrhotic liver, several
Japanese authors suggest that the adenomatous hyperplasia might be the
first step in the development of HCC, going through phases of dysplasic
nodule and small HCC in a multistep fashion4,34,48.
The objective of the present study was to compare the frequency of
abnormal immunohistochemical expression of p53 phosphoprotein in HCC
occurring in cirrhotic versus non-cirrhotic patients as well as in large liver
cell dysplasia (large cell dysplasia) and in adenomatous hyperplasia.
CASUISTIC AND METHODS
We studied 84 patients with hepatocellular carcinoma or cirrhosis.
54 patients were cases of hepatocellular carcinoma; 39 of them were
cirrhotic and 15 non-cirrhotic patients. The other 30 patients were
cirrhotic patients without hepatocellular carcinoma. Records were
retrieved from the Hepatology Branch, Department of Gastroenterology
or Division of Pathology of Hospital das Clínicas, São Paulo University
School of Medicine.
Immunohistochemical data analysis: All reactions were performed
at the Immunohistochemistry Laboratory, Adolfo Lutz Institute, the
Public Health Laboratory, São Paulo, Brazil.
The following primary monoclonal antibodies used were DO-7 (Dako,
USA), 1801 (Bio-gennex, USA) and DO-1 (Santa Cruz, USA). The epitopes
recognized by the antibodies are located between the N-terminal amino
acids 1-45 (DO-7), 46-55 (1801) and 37-45 (DO-1) of the human p53 protein.
Four-micrometer-thick histopathological sections were prepared from
formalin-fixed paraffin-embedded tru-cut needle liver biopsies. Antigen
retrieval was achieved with pressure cooker for 3 minutes. The specimens
were incubated overnight with the primary antibody at 4 °C. Amplification
was achieved by streptavidin-biotin-peroxidase (Dako Duet, USA) and, in
4 cases with cytoplasmic p53 staining where samples were still available, a
new reaction amplified with polymer-enzyme Envision-Alkaline Phosphatase
System (Dako, USA) was performed, thus assuring that reactivity was not
due to endogenous peroxidase or biotin (Fig. 1). The reaction products of
peroxidase were visualized by amplification with avidin-biotin-peroxidase
complex (Vector Laboratories, USA) and developed with H202 and diamino-
benzidine (Sigma Corp., USA).
One observer (VAFA) blinded to the clinical outcome of patients
performed assessment of staining21.
Chi square test was used for statistical analysis. All p values reported
are for a two-sided test, and the level of significance was set at 0.05.
RESULTS
In the present study, antibodies DO-7 and DO-1 yielded quite similar
results, with sharp nuclear staining in many neoplastic hepatocytes and
occasionally also in the cytoplasm of some tumor cells. Antibody 1801
was shown less sensitive with fewer cases positive, showing rather faible
nuclear staining.
In our sample, considering all the 54 patients with HCC, p53
immuno-expression was found in 19 patients (35.2%) (Fig. 1). Out of
39 cirrhotic patients with HCC, nuclear p53 expression was detected in
13 (33.3%). The comparison of p53 immuno-expression in 6 of 27 well
and moderately differentiated HCC (grades I or II)19,35,39 versus the 7 of
12 poorly differentiated (grades III or IV)18,30,34 a statistically significant
difference in the results obtained (Fig. 2). Nontumorous areas either in
the vicinity of HCC or in the 30 purely cirrhotic cases showed no p53
expression, even in foci of large cell dysplasia or adenomatous
hyperplasia. The reproducibility of this staining pattern in the 4 cases
where samples were still available for reaction with the recently
introduced Envision System-Alkaline Phosphatase demonstrate this is a
genuine pattern. These data shows a very high immuno-expression of
abnormal p53 in Brazilian patients mostly in those with high-grade
advanced tumors suggesting that p53 alteration occurs late in the
carcinogenesis. When we considered HBV, HCV or alcohol in the cases
studied, no significant difference was detected. In the noncirrhotic HCC
group the p53 expression was detected in 6 in 15 cases (40%), slightly
higher than in those occurring in cirrhotic patients.
DISCUSSION
Abnormal immunohistochemical expression of p53 was detected in
35.2% in the present Brazilian group of HCC patients, in a remarkable
similarity to the findings from PAIVA et al., reporting p53 immunoexpression
in 5/15 HCC cases also from São Paulo, Brazil51. Several studies have
indicated a relation between the p53 gene alteration and the development of
HCC41. This alteration occurs in the HCC of different causes, including
HBV and HCV infection, aflatoxin intake, hemochromatosis, and alfa1-
antitrypsin1,17,30,56. This alteration in p53 is linked to cellular events which
are accompanied by increased expression of several growth factors that
enhance the survival of carcinogen-activated cells by suppressing apoptosis
and increasing elements entering the cell cycle17,45. Trying to take this
correlation in order to improve the diagnosis and the prognosis knowledge
of this tumor, we studied the p53 immuno-expression using a
immunohistochemical method with monoclonal antibodies to different
epitopes of N-terminal region of p53 DO-7, 1801 and DO-1.
We could not find significant differences in the p53 expression in
cirrhotic versus noncirrhotic patients with HCC contrasting to results of
high-throughput gene analysis using cDNA microarrays study which
supported the idea of different genetic alterations in HCC with or without
cirrhosis53.
Higher detection of p53 alteration in advanced grade tumor (GRADE
III-IV) and absence of that alteration in dysplastic and adenomatous
hyperplastic areas in the vicinity of the tumor are in agreement with a
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research which shows p53 gene alteration of 15% and 52% in moderately
and poorly differentiated HCCs respectively and not at all in well
differentiated HCC. Since in the preferential pathway for liver cell
carcinogenesis, early/small hepatocellular carcinomas are usually well-
differentiated (grades I and II) whereas advanced/large carcinomas are
preferentially grades III-IV, this finding further demonstrates that p53
alterations are late event in hepatocarcinogenesis. Another study that
examined p53 gene by PCR-RFLP also corroborates to this conclusion,
showing a p53 mutation rate of 10%, 55.2% and 80.8% in the well-,
moderately- and poorly-differentiated HCC respectively32. In contrast,
it was demonstrated that in animals the p53 gene mutations is present in
initial hepatocarcinogenesis22, and HUANG et al. showed that in humans
a serine substitution at codon 249 of the p53 gene might serve as a new
early diagnostic marker for HCC29.
Moreover, it was showed in a Japanese study that the spectrum of
p53 mutation did not differ among HCCs in relation to the type of hepatitis
virus infection, sex, age, and background liver disease of patients, tumor
size or presence of metastasis, however incidence and site were
significantly associated with the degree of differentiation of cancer cells.
Using Single Strand Conformation Polymorphism analysis, it was found
54% of p53 mutation in poorly differentiated HCC while the mutation
was less frequent (21%) in well or moderately differentiated HCC46.
p53 gene mutation is suggested to occur independently of the type
of infection or status of preexisting liver disease, as well showed in our
research where HBV, HCV or alcohol was not a factor of difference in
the mp53 expression46. However, in a recent study, ALTAF found p53
Fig. 2 - p53 immuno-expression versus histological grade.
Fig. 1 - Immuno-expression of p53 is abundant in nuclei, whereas cytoplasmic immunostaining is found in occasional neoplastic cells (DO-7, Envision Alk. Phosphatase, x 200).
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immunoexpression in 52% of cases and 53% of them were having anti
hepatitis B surface antigen positivity, detected in their serum and 23%
were having hepatitis C antibodies positive2. On the other hand, DING
et al. found only 20 p53 point mutation at exon 7 in 239 HCC samples
examined16.
In a study using immunohistochemical detection for mutant p53
protein with monoclonal antibody PAb1801, TERAMOTO et al. found
p53 overexpression in 22 tumours (31%) but in none of the non-tumorous
liver specimens54. Overexpression of p53 was more frequent in poorly
differentiated tumours (p = 0.01), in tumours > 5 cm (p = 0.05), and in
those presenting giant cells (p = 0.03). No significant correlation with
hepatitis B or C status, background liver disease was detected, suggesting
that p53 mutation in HCC was a late event in HCC54. The present study,
along with other papers further corroborate this hypothesis2,60.
In a study that has assessed p53 expression by immunoluminometric
assay on liver samples from 40 patients with biopsy-proven HCV-related
chronic hepatitis, was found an overexpression of p53 in 17.5% of them
and this p53 positive group had a daily ethanol intake significantly higher
in respect to that of the p53 negative group (p < 0.05)18. Another study
found that tumors associated with alcoholism had more frequent
alterations in the p53 pathway than those caused by HCV infection20. In
our study, a different factor related to carcinogenesis of HCC is also
evident, since no difference was found among patients with HBV, HCV
or alcoholic influence.
Regarding the less commonly reported finding of cytoplasmic p53
immunoexpression, the reproducibility of results in cases with enough
sample in the block for the repetition of the reaction with the new
polymer-enzyme Envision method reinforces the hypothesis that this
may be an odd, but genuine localization of p53, as previously suggested
by ZHAO et al.59 and by ZERBINI et al.58. In a recent experiment OH et
al. showed that bile duct ligation shifts p53 immunohistochemical
expression from nuclei to cytoplasm and advocate that such shifting
could play an important role in induction of apoptosis47.
CONCLUSION
In this study we tried to correlate the immunohistochemical expression
of altered p53 (mp53) to the degree of alterations of hepatic cells.
We found a frequency of mp53 expression in HCC of 35.2%, which
is intermediate between data from USA (6-18%) and Africa (40-50%)
where this alteration would be related to aflatoxin. Moreover, it was not
found a significant difference between cirrhotics versus non-cirrhotics,
as well as among HBV and HCV and alcoholic suggesting another
triggering factor for such alteration in Brazil. The higher frequency of
aberrant immuno-expression of p53 in less differentiated HCCs further
demonstrates that p53 alterations are late phenomena in liver
carcinogenesis.
Future studies should be aimed at mapping hot spot areas of p53
mutation as well as at assessing the possible role of other etiological
agents, including toxics, such as aflatoxins and organic contaminants in
HCC in Brazil.
RESUMO
Expressão imunohistoquímica do p53 carcinoma hepatocelular de
pacientes brasileiros
O carcinoma hepatocelular (CHC) é um importante tipo de câncer
relacionado etiologicamente a alguns vírus, carcinógenos químicos e outros
fatores ambientais que causam danos crônicos ao fígado em humanos. A
freqüência de mutação do gene p53 em CHC é altamente heterogênea (0-
52%) nos diversos países. OBJETIVO. O objetivo deste estudo foi
determinar, imuno-histologicamente, a freqüência da expressão anômala
de p53 em CHCs em pacientes cirróticos versus não-cirróticos, bem como
em displasia hepática e hiperplasia adenomatosa. Para isso, foram estudados
84 pacientes com carcinoma hepatocelular ou cirrose. RESULTADOS.
Foram detectadas expressões do p53 alterado em 58,3% dos pacientes
com CHC graus III-IV, contrastando com os 22,2% dos pacientes com
CHC graus I-II (p = 0,02). Áreas não tumorais, tanto nas proximidades do
CHC como nos 30 casos de cirrose não mostraram expressão nuclear
alterada do p53, mesmo nas displasias ou hiperplasias adenomatosas.
Quando se considerou HBV, HCV ou alcoolismo nos casos estudados,
não se encontrou diferença significativa. CONCLUSÃO. A elevada
freqüência de imuno-expressão de p53 nesta população é próxima à relatada
na China e África, tornando necessárias outras pesquisas para explicar as
diferenças com os CHC estudados na Europa e na América do Norte.
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